The distinct signatures of VEGF and soluble VEGFR2 increase prognostic implication in gastric cancer.

Abstract

Recently, an anti-angiogenic strategy to treat gastric cancer (GC) has been successful with the use of ramucirumab. The comprehensive network of VEGF, soluble VEGF receptor-2 (sVEGFR2) and cytokines and other angiogenic factors (CAF) in GC has not been reported. We aimed to reveal the CAF signature associated with VEGF and sVEGFR2, and to explore their… (More)

Topics

  • Presentations referencing similar topics